topotecan hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
topotecan hydrochloride: clinical details
Prescribing considerations
- Restrict prescribing and administration to specialist cytotoxic chemotherapy services.
- Assess performance status, renal and hepatic function, previous treatment and bleeding risk.
- Oral treatment requires proactive diarrhoea counselling and management; consider whether vomiting, swallowing problems or altered gastrointestinal absorption make the oral route unsuitable.
- Review pulmonary history and concurrent pneumotoxic treatment because interstitial lung disease has been reported.
Contraindications and cautions
- Severe hypersensitivity to topotecan or an excipient
- Breastfeeding
- Severe bone-marrow depression before the first course
Monitoring
- Full blood count, including neutrophils, haemoglobin and platelets, before and during treatment
- Renal and hepatic function
- Fever, infection, bleeding and gastrointestinal toxicity
- New respiratory symptoms suggestive of interstitial lung disease
- Clinical performance status before further treatment
Clinical pharmacology
Topotecan is a camptothecin-derived topoisomerase I inhibitor. It stabilises the cleaved DNA–enzyme complex, producing protein-associated DNA strand breaks. The active lactone undergoes reversible hydrolysis; renal elimination is clinically important, and oral bioavailability is incomplete.
Formulation and product differences
- Topotecan Hospira is a sterile yellow to yellow-green concentrate requiring further dilution before intravenous administration.
- Hycamtin is supplied as hard capsules that must remain intact and may be taken with or without food.
- The selected infusion product covers ovarian cancer, relapsed small-cell lung cancer and cervical cancer with cisplatin; the selected capsule product covers adult relapsed small-cell lung cancer only.
- Oral topotecan has a prominent risk of severe diarrhoea and exposure can rise with certain transporter inhibitors.
topotecan hydrochloride preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 4 mg/4 mL
Capsule
Route: Oral
Strengths: 0.25 mg, 1 mg
topotecan hydrochloride interactions
The oncology team should review all prescribed, over-the-counter and complementary products before treatment.
Cyclosporin and other ABCB1 or ABCG2 transporter inhibitors
These can substantially increase exposure to oral topotecan, requiring close monitoring for toxicity.
Other cytotoxic chemotherapy
Combined treatment can increase toxicity, particularly bone-marrow suppression, and must be specialist managed.
Cisplatin or carboplatin
Tolerability depends partly on treatment sequence, so the combination must follow the specialist protocol.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.